[1] 赵凯凯, 白俊琴, 张波. 新型P2Y12受体拮抗剂替格瑞洛广谱抗血小板作用机制的研究进展[J]. 中国动脉硬化杂志, 2022, 30(2):180
ZHAO KK, BAI JQ, ZHANG B. Research progress on the mechanisim of broad-spectrum antiplatelet effect of novel P2Y12 receptor antagonist ticagrelor [J]. Chin J Arterioscler, 2022, 30(2):180
[2] DEEKS ED. Ticagrelor [J]. Drugs, 2011, 71(7):909
[3] DOBESH PP, OESTREICH JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety[J]. Pharmacotherapy,2014,34(10):1077
[4] HUSTED S, GIEZEN JJJV. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist[J]. Cardiovasc Ther, 2009, 27(4):259
[5] BOHLIN M, COSGROVE S, LASSEN B. Crystalline and Amorphous form of Triazolo (4,5-d) Pyrimidine Compound: US, 7265124[P]. 2007-09-04
[6] 胡秀荣, 吴佳佳, 沈金, 等. 替格瑞洛的一水合物及其制备方法与在制药中的应用: 中国, 104341423[P]. 2015-02-11
HU XR, WU JJ, SHEN J, et al. Ticagrelor Monohydrate, Preparation Method Thereof and Pharmaceutical Application Thereof: China, 104341423[P]. 2015-02-11
[7] 胡晨阳, 任芳俊, 盛晓霞, 等. 替卡格雷晶型及其制备方法和用途: 中国, 104098570[P].2014-10-15
HU CY, REN FJ, SHENG XX, et al. Crystal form of Ticagrelor Brilinta and Preparation Method and Purpose Thereof: China, 104098570[P].2014-10-15
[8] 袁建栋, 陈敏华. 替卡格雷晶型及其制备方法:中国, 103772393 [P]. 2014-05-07
YUAN JD, CHEN MH. Ticagrelor Crystal Forms and Preparation Method Thereof: China, 103772393 [P]. 2014-05-07
[9] 周付刚, 张雅然, 马玉秀, 等. 一种替卡格雷新结晶及其制备方法: 中国, 104710425[P]. 2015-06-17
ZHOU FG, ZHANG YR, MA YX, et al. Ticagrelor New Crystal and Preparation Method Thereof: China, 104710425[P]. 2015-06-17
[10] 郭璠, 黄文武, 郑少军, 等. 替格瑞洛的新结晶形式及其制备方法和用途: 中国, 105418614[P]. 2016-03-23
GUO F, HUANG WW, ZHENG SJ, at al. New Crystal Form of Ticagrelor as well as Preparation Method and Application Thereof: China, 105418614[P]. 2016-03-23
[11] 尚德斌, 姜维平, 贾春荣. 一种替格瑞洛新晶型S及其在药物制剂中的应用: 中国, 108203436[P].2018-06-26
SHANG DB, JIANG WP, JIA CR. Novel Crystal form S of Ticagrelor, and Application of Same to Medicinal Preparations: China, 108203436[P]. 2018-06-26
[12] 季伟杰.替格瑞洛的多晶型行为研究[D].杭州: 浙江工业大学, 2016
JI WJ. The Study of Ticagrelor Polymorphism Behaviors [D].Hangzhou: Zhejiang University of Technology, 2016
[13] 喻红梅, 房政钰, 邢逞, 等. 替格瑞洛新盐型的制备、表征及溶解性能研究[J]. 药学学报, 2021, 56(2):570
YU HM, FANG ZY, XING C, et al. Preparation, characterization and improved solubility of ticagrelor salts[J]. Acta Pharm Sin, 2021, 56(2):570
[14] INAM M, WU JJ, SHEN J, et al. Preparation and characterization of novel pharmaceutical co-crystals: ticagrelor with nicotinamide[J]. Crystals,2018, 8:336
[15] YANG S, WU Y, ZHANG H, et al. Solubility measurement of crystal form Ⅱ and form V ticagrelor in several pure organic solvents[J]. J Chem Eng Data, 2021,66:2022
[16] 申建伟, 赵金红, 吴晶, 等. 替格瑞洛晶型热力学稳定性关系研究[J]. 中国处方药, 2022,20(3):33
SHEN JW, ZHAO JH, WU J, et al. Study on thermodynamic stability relationship of ticagrelor polymorph[J]. J China Prescripn Drug, 2022,20(3):33
[17] REN Y, SHEN J, YU K, et al. Impact of crystal habit on solubility of ticagrelor[J]. Crystals, 2019, 9:556
[18] BOJARSKA J, REMKO M, FRUZIѝSKI A, et al. The experimental and theoretical landscape of a new antiplatelet drug ticagrelor: Insight into supramolecular architecture directed by CH…F, π…π and CH…π interactions[J]. J Mol Struct, 2018, 1154: 290
[19] HARTMAN P, PERDOK WG. On the relations between structure and morphology of crystals I [J]. Acta Crystallograph, 1955, 8(1):49
[20] INOUE M, HIRASAWA I. The relationship between crystal morphology and XRD peak intensity on CaSO4·2H2O[J]. J Cryst Growth, 2013,380:169
[21] 朱炯, 吴建敏, 黄海伟, 等. 差示扫描量热法在药品检验中的研究进展[J]. 中国药事, 2018, 32(2):210
ZHU J, WU JM, HUANG HW, et al. Research progress of differential scanning calorimetry in drug testing[J]. Chin Pharm Aff, 2018, 32(2):210
[22] BARBAS R, MARTÍ F, PROHENS R, et al. Polymorphism of norfloxacin: Evidence of the enantiotropic relationship between polymorphs A and B[J]. Cryst Growth Des, 2006, 6: 1463
[23] ZENCIRCI N, GELBRICH T, APPERLEY DC, et al. Structural features, phase relationships and transformation behavior of the polymorphs Ⅰ-Ⅵ of phenobarbital[J]. Cryst Growth Des, 2010, 10: 302
[24] BORCHERT C, TEMMEL E, EISENSCHMIDT H, et al. Image-based in situ identification of face specific crystal growth rates from crystal populations[J]. Cryst Growth Des, 2014, 14(3):952
[25] CHOW K, TONG HHY, LUM S, et al. Engineering of pharmaceutical materials: an industrial perspective[J]. J Pharm Sci, 2008, 97(8):2855
[26] RAMAMOORTHY S, KWAK JH, KARANDE P, et al. A high-throughput assay for screening modifiers of calcium oxalate crystallization[J]. AIChE J, 2016, 62(10):3538
[27] KLAPWIJK AR, SIMONE E, NAGY ZK, et al. Tuning crystal morphology of succinic acid using a polymer additive[J]. Cryst Growth Des, 2016, 16(8):4349
